<p>Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines.</p><p><br></p><p>We discuss how Immunethep could challenge Pfizer’s $7bn+ Prevnar, and how one pharma company got on board after a representative said he doesn’t believe in vaccines!</p><p><br></p><p>---</p><p><br></p><p>For transparency, this episode has been sponsored by Immunethep. Learn more at <a href="https://bit.ly/flot-immunethep" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/flot-immunethep</a></p><p><br></p><p>---</p><p><br></p><p><br></p><p>⭐️ ABOUT THE SPEAKERS</p><p><br></p><p><br></p><p>Bruno is Immunethep’s co-founder and CEO, and co-founder of the startup creator Venture Catalysts. He also co-founded the tech startup Abyssal, which was acquired by marine robotics company Ocean Infinity in 2021.</p><p><br></p><p>Co-founder and CSO Pedro is a biomedical scientist previously serving as an Assistant Researcher at i3S. He has a PhD in Biomedical Sciences from the University of Porto and boasts over 30 peer-reviewed publications.</p><p><br></p><p><br></p><p>🔗 LINKS MENTIONED</p><ul><li>Immunethep website — <a href="https://www.immunethep.com/" target="_blank" rel="ugc noopener noreferrer">https://www.immunethep.com/</a></li><li>When Cancer is no longer the biggest threat: AMR’s growing shadow over oncology — <a href="https://www.incate.net/when-cancer-is-no-longer-the-biggest-threat-amrs-growing-shadow-over-oncology/" target="_blank" rel="ugc noopener noreferrer">https://www.incate.net/when-cancer-is-no-longer-the-biggest-threat-amrs-growing-shadow-over-oncology/</a></li><li>Antimicrobial resistance WHO page — <a href="https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance" target="_blank" rel="ugc noopener noreferrer">https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance</a></li><li>Center for Global Development: The Economics of Antibiotic Resistance — <a href="https://www.cgdev.org/sites/default/files/economics-antibiotic-resistance.pdf" target="_blank" rel="ugc noopener noreferrer">https://www.cgdev.org/sites/default/files/economics-antibiotic-resistance.pdf</a></li><li>GSK completes Affinivax acquisition — <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/" target="_blank" rel="ugc noopener noreferrer">https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/</a></li><li>António Portela, BIAL 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54 —<a href="https://flot.bio/episode/antonio-portela-bial-parkinsons-biopharma/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/antonio-portela-bial-parkinsons-biopharma/</a></li></ul><p><br></p><p><br></p><p>📜 TRANSCRIPT</p><p><br></p><p>Read the full transcript here: <a href="https://flot.bio/episode/immunethep-antimicrobial-resistance/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/immunethep-antimicrobial-resistance/</a></p><p><br></p><p><br></p><p>💸 DONATE</p><p><br></p><p>We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: <a href="https://www.paypal.me/PhilipHemme" target="_blank" rel="ugc noopener noreferrer">https://www.paypal.me/PhilipHemme</a></p><p><br></p><p><br></p><p>⭐️ SPONSORSHIP</p><p><br></p><p><br></p><p>Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!</p><p><br></p><p><br></p><p>🫶 FOLLOW US</p><ul><li>Newsletter: <a href="http://eepurl.com/h_fnmH" target="_blank" rel="ugc noopener noreferrer">http://eepurl.com/h_fnmH</a></li><li>LinkedIn: <a href="https://www.linkedin.com/company/flot-bio/" target="_blank" rel="ugc noopener noreferrer">https://www.linkedin.com/company/flot-bio/</a></li><li>X (Twitter): <a href="https://x.com/FlotBio" target="_blank" rel="ugc noopener noreferrer">https://x.com/FlotBio</a></li></ul><p><br></p><p><br></p><p>🙏 LIKE/FOLLOW/REVIEW</p><p><br></p><p><br></p><p>Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.</p><p><br></p><p><br></p><p>🎙️ ABOUT FLOT.BIO</p><p><br></p><p><br></p><p>Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.</p><p><br></p><p><br></p><p>⏰ TIMESTAMPS</p><p><br></p><ul><li>[00:00:00] Intro</li><li>[00:02:10] The overlooked antimicrobial resistance crisis</li><li>[00:10:26] Immunethep: When Bruno Santos and Pedro Madureira teamed up</li><li>[00:15:41] Taking down multiple superbugs with a single vaccine</li><li>[00:27:30] Preparing to challenge Pfizer’s $7bn+ Prevnar</li><li>[00:42:11] The Portuguese biotech ecosystem</li><li>[00:46:10] Bruno Santos’ cross-disciplinary experience</li><li>[00:48:09] Not taking ‘no’ for an answer from big pharma</li><li>[00:51:44] Immunethep’s IP and tech transfer achievements </li><li>[00:55:44] Quick-fire questions</li></ul>